[RESEARCH BLOG] · 2026-10-02
STTK (Shattuck Labs, Inc.) – Phase‑2 Trial Launch Fuels BUY Signal in Recovery Regime
By Pierre Brunelle · Founder & Research Lead
Shattuck Labs closed at $6.84, up 0.29 % as of 2026‑10‑01 (Thursday, US session). The biotech’s latest clinical‑development milestone and fresh institutional backing have aligned with LOPJLB’s strongest BUY rating, prompting a spotlight on the stock amid a broader market recovery.
Shattuck Labs announced on October 1, 2026 that its experimental antibody SL‑325 has entered a Phase 2 clinical trial for hidradenitis suppurativa, a chronic inflammatory skin disease with limited therapeutic options. The company also named Dr. Shoba Ravichandran as Senior Vice President of Clinical Development, underscoring a deepening executive bench as the trial progresses through multiple dosing cohorts. The press release highlighted that the Phase 2 protocol will enroll up to 150 patients across 20 U.S. sites, with primary endpoints focused on lesion reduction and patient‑reported outcome measures. See the full announcement here:
Shattuck Labs Announces Phase 2 Clinical Trial of SL-325 in Hidradenitis Suppurativa and Appointment of Shoba Ravichandran, M.D., as Senior Vice President, Clinical Development
Earlier in September, Frazier Life Sciences Management L.P. disclosed the purchase of 3,750,000 shares of STTK, a transaction that added roughly $25 million of equity capital at prevailing market prices. The filing indicated that the investment was part of Frazier’s strategic allocation to emerging immuno‑oncology platforms, reflecting confidence in Shattuck’s pipeline beyond the SL‑325 asset. Details are available in the filing:
3,750,000 Shares in Shattuck Labs, Inc. $STTK Purchased by Frazier Life Sciences Management L.P.
Just two days before the Frazier purchase, BlackRock Inc. reported a $27.32 million investment in Shattuck Labs, marking the asset manager’s first direct exposure to the company. BlackRock’s investment memo, referenced in the filing, cited “the compelling pre‑clinical data on TL1A modulation” and the “potential for a differentiated therapeutic approach in both oncology and autoimmune indications” as primary catalysts for the allocation. The announcement can be read here:
BlackRock Inc. Invests $27.32 Million in Shattuck Labs, Inc. $STTK
In late August, a series of analyst pieces highlighted the TL1A boom—a surge in investor interest around therapies targeting the tumor necrosis factor superfamily member TL1A. Shattuck’s pipeline, which includes the TL1A‑targeted candidate SL‑172154 currently in Phase 1 for ovarian and fallopian tube cancers, was positioned as a “receptor‑side bet” that could capture a sizable share of a market projected to exceed $12 billion by 2030. Key coverage includes:
- Shattuck Labs: A Receptor-Side Bet On The TL1A Boom (Seeking Alpha, 2026‑09‑01)
- What Shattuck Labs Stock Topped the Market on Monday (The Motley Fool, 2026‑08‑24)
- Shattuck Labs, Inc. (STTK) is a Great Momentum Stock: ? (Zacks, 2026‑08‑20)
- Geron (NASDAQ:GERN) and Shattuck Labs (NASDAQ:STTK) Head to Head Comparison (DefenseWorld, 2026‑08‑14)
- Wall Street Analysts Believe Shattuck Labs (STTK) Could Rally 85.31%: Here's is How to Trade (Zacks, 2026‑08‑13)
- Why Shattuck Labs Stock Flew Nearly 5% Higher on Friday (The Motley Fool, 2026‑07‑24)
Shattuck also announced its participation in upcoming September investor conferences, a move that may broaden exposure to institutional audiences:
Shattuck Labs Announces Participation in Upcoming September Investor Conferences (GlobeNewswire, 2026‑09‑02)
Collectively, this coverage underscores a growing market narrative that positions Shattuck Labs as a compelling play on emerging TL1A‑targeted therapeutics, with a market‑cap of $618.1 million that still leaves ample upside if early‑stage data translate into later‑stage efficacy.
Fundamentals and Valuation
Shattuck Labs operates at the clinical‑development stage, meaning that traditional profitability metrics remain negative while the firm invests heavily in research, regulatory filings, and trial execution. The trailing twelve‑month (TTM) price‑to‑earnings (P/E) ratio sits at ‑13.67, reflecting a loss‑making profile typical for biotech firms still awaiting pivotal trial readouts. The enterprise‑value‑to‑EBITDA (EV/EBITDA) multiple is ‑11.51, reinforcing the notion that earnings before interest, taxes, depreciation, and amortization are currently negative.
Margin analysis paints a stark picture of ongoing cash burn. Gross margin is ‑750.9 %, operating margin plunges to ‑5,578.7 %, and net margin trails at ‑5,256.8 %. These figures are consistent with a company that has yet to commercialize a product and is financing its pipeline through equity raises and strategic partnerships. Nevertheless, the return on invested capital (ROIC) of ‑26.14 %, return on equity (ROE) of ‑43.57 %, and return on assets (ROA) of ‑23.82 % all signal that capital is being deployed in high‑risk, high‑potential research activities rather than generating immediate shareholder returns.
The balance sheet shows a debt‑to‑equity (D/E) ratio of 1.27, indicating modest leverage for a biotech that relies primarily on equity financing. The price‑to‑book (P/B) ratio of 4.29 suggests that the market is already pricing in a premium for the company’s intellectual property and pipeline potential, despite the lack of revenue. Analyst consensus projects a target price of $13.20, effectively a 92 % upside from the current $6.84 close, and the analyst recommendation is a Buy.
A snapshot of the valuation metrics is shown below:
| Metric | Value |
|---|---|
| P/E (TTM) | ‑13.67 |
| EV/EBITDA | ‑11.51 |
| P/B | 4.29 |
| D/E | 1.27 |
| Analyst Target | $13.20 |
| Market Cap | $618.1 M |
Revenue trends remain modest as the company has not yet launched a commercial product. 2020 revenue was $9.93 M, climbing to $30.02 M in 2021, before falling to $0.65 M in 2022 as the firm re‑focused on its core pipeline. The most recent fiscal year (2025) reported $1.00 M in revenue, a modest increase over the prior year’s $0.57 M. Earnings per share (EPS) have been consistently negative, ranging from ‑$0.88 in 2020 to ‑$0.70 in 2025, reflecting ongoing R&D expense outlays.
Free cash flow (FCF) has been persistently negative, with a ‑$39.95 M outflow in 2025, down from ‑$60.57 M in 2024. The cumulative cash burn underscores the importance of external financing, which has been partially satisfied by the recent BlackRock and Frazier investments. The discounted cash‑flow (DCF) valuation component in LOPJLB’s model accounts for 1,106.9 % of the total valuation, indicating that the methodology heavily weights future cash‑flow projections once the pipeline advances to revenue‑generating stages.
Historical margins illustrate the volatility typical of early‑stage biotech firms. Gross margins swung from ‑277.3 % in 2020 to a modest +14.46 % in 2024, before slipping back to ‑195.1 % in 2025. Operating margins have been even more erratic, moving from ‑371.8 % in 2020 to ‑1,408.3 % in 2024, then easing to ‑5,150.8 % in 2025. Net margins have followed a similar trajectory, with the most recent figure of ‑4,880.9 % in 2025. These swings are driven largely by the timing of clinical trial expenses, regulatory fees, and the occasional infusion of capital that temporarily improves the balance sheet.
Despite the negative profitability metrics, the quality score in LOPJLB’s composite framework is 0.00, reflecting the company’s early‑stage risk profile. Conversely, the value score of 6.00 and growth score of 4.00 suggest that the market perceives a blend of undervaluation relative to peers and upside potential from pipeline milestones. The GARP score of 3.60 places Shattuck in a middle‑ground where growth expectations are tempered by current valuation constraints.
ETF Ownership
Institutional exposure to Shattuck Labs is concentrated in two thematic exchange‑traded funds that focus on oncology and medical‑device innovation. The CNCR ETF holds 3.23 % of STTK’s outstanding shares, ranking the stock at #25 within the fund’s holdings. The TMED ETF carries a 1.43 % stake, placing Shattuck at #26 in that portfolio.
Concentrated ETF ownership can affect liquidity and price dynamics, especially when the funds rebalance around earnings seasons or when they respond to macro‑level shifts in biotech sentiment. Investors should be aware that a sizeable reallocation by either fund could introduce short‑term volatility, even as the underlying fundamentals remain driven by trial outcomes and regulatory milestones.
LOPJLB Signal Read
The LOPJLB model currently issues a BUY directional signal for STTK, with a Score of 5—the highest confidence tier in the system. The signal is generated within a RECOVERY market regime, indicating that the broader equity environment has transitioned from a contractionary phase to one where risk assets are regaining momentum. The composite PERF score of 25.50 and a Quality score of 0.00 reflect the model’s emphasis on upside potential rather than current profitability.
STTK’s archetype is “Balanced,” blending modest value characteristics (Value = 6.00) with growth attributes (Growth = 4.00) and a GARP tilt (GARP = 3.60). This balanced profile suggests that the stock may appeal to investors seeking exposure to high‑impact biotech innovation while still maintaining a disciplined valuation perspective.
Readers interested in the full overlay of technical and quantitative signals should consult the interactive chart on the LOPJLB stock page. The chart visualizes the BUY signal, the recovery regime, and the underlying factor scores in real time. For a deeper dive into the methodology that powers these signals, visit the LOPJLB methodology page.
For the latest price action, detailed financial tables, and the full suite of LOPJLB analytics, explore the dedicated STTK page at lopjlb.com/stock/STTK. If you wish to review the most recent earnings‑call commentary (when available), see lopjlb.com/stock/STTK/earnings.md. To screen for other biotech opportunities with similar signal characteristics, use the LOPJLB screener.
The content above is for informational research purposes only and does not constitute investment advice. All investors should conduct their own due diligence and consider their risk tolerance before making any investment decisions.
This post is independent quantitative research, not investment advice. LOPJLB signals are model outputs derived from price, volume, and fundamentals. Past backtests do not guarantee future results. Position sizing, execution, and risk management remain the reader's responsibility.